Den tredje undersøgelse omfattede 459 patienter, der havde fået tre antivirale lægemidler (herunder lamivudin) i mindst 12 uger og havde et lavt indhold af hiv i blodet.
The third study included 459 patients who had been taking three antiviral medicines (including lamivudine) for at least 12 weeks and had low levels of HIV in their blood.